TaiMed CEO James Chang says bluntly that the US $ 40 million (NT $ 1.4 billion) cost of large-scale Phase III trials will compel TaiMed to partner with a major international firm to further the drug's development in the American style. TaiMed estimates that within its first 10 years on the market, the drug could reach total sales of as much as US $ 2 billion.
中裕新藥執行長張念原說得很明白，面對未來進入大規模第三期臨床試驗之後所需的 4,000 萬美元（14 億元台幣），中裕一定會「走美國的模式」尋求與國際大廠結盟，甚至不惜賣出專利；估計產品成功上市 10 年之後，銷售總額可達 20 億美金。